Regulatory approval announcements from authorities like FDA, EMA, or similar

Biomea Fusion's Icovamenib-Semaglutide Combo Yields 11.5% Weight Loss, 43% Muscle Gain, and 60% Better Glucose Control

Jan 7, 2025, 12:02 PM

Biomea Fusion Inc. has announced compelling results from a preclinical study evaluating the combination of icovamenib, an investigational covalent menin inhibitor, with semaglutide, a GLP-1 receptor agonist. The study, conducted on Zucker Diabetic Fatty rats, demonstrated that the combination therapy led to an additional 11.5% body weight reduction, a 43% increase in lean muscle mass, and a 60% improved glucose control compared to semaglutide alone. Furthermore, the combination therapy resulted in a 60% reduction in fasting blood glucose levels and improved glucose metabolism, as indicated by a 50% reduction in the area under the curve during the Oral Glucose Tolerance Test. These findings suggest that icovamenib could enhance the effects of GLP-1 therapies, potentially offering a new approach to managing type 2 diabetes and obesity.